MedTrace Logo

to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection

NCT06437951 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-06-03

No results posted yet for this study

Summary

to evaluate the safety/tolerability and pharmacokinetics, and pharmacodynamics after intravenous DWP14012 injection in healthy participants

Conditions

  • Erosive Gastroesophageal Reflux Disease

Interventions

DRUG

Fexuprazan Injection

20/40/80 mg

DRUG

Fexuprazan Injection placebo

20/40/80 mg

DRUG

Fexuprazan Injection_part 2

20mg

DRUG

Fexuprazan Injection_part 3

40mg

DRUG

Fexuprazan tablet

40mg

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • Injin zhang, Ph.D · Seoul National University College of Medicine and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-31
Primary Completion
2025-01-31
Completion
2025-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06437951 on ClinicalTrials.gov